

Imperial College Healthcare MHS

**NHS Trust** 

# What do we know about GBM Patient pathways in England ?

#### Matt Williams, ICHNT

#### David Greenberg, PHE

On behalf of the NCIN Brain CNS SSCRG

#### April 2016





## Background

- Previously published data on GBM incidence and treatment in England 2007 – 2012
- > 10 000 pts
- Incidence & Survival
- Some treatment data
- Nothing on RT dose/ frac, surgery, chemotherapy
- These details are important
  - To lots of people

## Aims

- To develop a detailed patient cohort of GBM patients in England
- To understand treatment, and variations in treatment pathways
- Some key questions:
  - Are there variations in surgery vs. biopsy ?
  - Treatment rates, and types of treatment ?
  - Times to treatment ?
- Interesting for brain tumours, but also other sites
- Pts often require complex, multi-disciplinary treatment


### Data

- 2477 patients with cranial glioblastoma (ICD10 site C71\*, ICD10-O2 morphology 9440/3. 9441/3 and 9442/3) diagnosed in 2013 in residents of England were extracted from the PHE Cancer Analysis System (CAS)
- These patients were matched with their records in:
  - Hospital Episode Statistics (HES) inpatient dataset (HESAPC)
  - Hospital Episode Statistics (HES) outpatient dataset (HESOP)
  - National Radiotherapy Dataset (RTDS)
  - Systemic Anti-Cancer Therapy Dataset (SACT)
  - Cancer Waiting Times Dataset (CWT)

## Results so far

- Remains a work in progress
- However, we have identified the patients, and linked key data sources
- One of the difficult questions is how to resolve conflicting and overlapping data sources

#### Debulking surgery for GBM in England, 2013 Triangulating national data sources



Encore	HES Inpatients	HES Outpatients	Cancer Waiting Times	Cases
-	-	-	-	981
✓	4	-	✓	939
✓	√	-	-	277
-	√	-	✓	82
-	√	-	-	63
✓	-	-	-	55
-	-	-	4	45
✓	-	-	√	34
1	1	1	1	1


40% of GBM patients had no debulking surgery

The proportion of debulking records found: 91% in **inpatient HES**; 87% in **Encore** 74% in **Cancer Waiting Times** 

Reassuringly, there were almost no records of **outpatient** debulking surgery.

**Encore** and **inpatient HES** are the most meaningful sources of debulking surgery data.

#### Radiotherapy treatments for GBM in England, 2013 Triangulating national data sources



•Number of patients in 2013 diagnosed with Glioblastoma

•2,477

•GBM patients with no radiotherapy treatment recorded

•901 (36%)

•Of all GBM patients with a radiotherapy record, those with a record in the Radiotherapy Dataset (RTDS)

•1,537 (98%)

#### Radiotherapy treatments for GBM in England, 2013 Interpretation


Encore	RTDS	HES Outpatients	HES Inpatients	сwт	Number of cases
-	-	-	-	-	901
1	1	-	-	\$	293
✓ ✓	1	_	-	-	291
1	1	4	-	4	269
<b>√</b>	1	4	-	-	224
-	1	-	-	-	144
-	1	*	-	-	107
1	1	-	1	-	107 63
- 	1	-	1	4	54
1	1	4	1	-	26 21
1	1	*	1	\$	21
-	1	-	1	-	18
-	1	_	-	\$	11
1	-	-	-	-	10
- - - -	1	4	-	\$	8
1	-	4	-	1	5
1	-	-	-	1	5
-	1	-	1	✓	5 5 5 5
-	-	1	-	-	5
-	-	-	1	-	4
-	-	1	-	-	3
1	-	-	1	-	3
-	$\checkmark$	✓	1	-	3
-	-	-	-	1	3
<ul> <li>✓</li> </ul>	-	4	1	-	1

•**RTDS** and **Encore** were by far the most common data sources to find GBM patient radiotherapy treatment information.

•There is a notably higher completeness of data in RTDS as compared with Encore. In 2013, there are few cases that have a radiotherapy record in Encore but do not have one in RTDS.

•RTDS should hold data on doses, fractions, intent, etc., so for more detailed analysis, it would be advisable to use 2013 RTDS.

#### Chemotherapy treatments for GBM in England, 2013 Triangulating national data sources



•Number of patients in 2013 diagnosed with Glioblastoma

•2,477

•GBM patients with no chemotherapy treatment recorded

•1,270 (51%)

•Of all GBM patients with a chemotherapy record, those with a record in the Systemic Anti-Cancer Therapy dataset (SACT)

•851 (71%)

#### Chemotherapy treatments for GBM in England, 2013 Interpretation

Encore	SACT	HES Inpatients	HES Outpatients	сүт	Number of cases
-	-	-	-	-	1270
<ul><li>✓</li><li>✓</li></ul>	4	-	ł	4	136
	4	4	-	4	125
4	4	4	ł	4	106
*	4	-	*	-	99
4	4	4	-	-	66
-	4	-	✓	-	63
4	- ✓	-	-	4	60
-	-	×	-	-	59
-	-	-	*	-	55
<ul> <li>✓</li> <li>✓</li> </ul>	4	4	ł	-	52
	-	-	-	4	49
-	4	-	-	-	34
4	-	-	-	-	32
-	-	-	-	4	28
-	4	-	4	4	28
1	-	-	*	4	26
1	4	-	-	-	25
<ul> <li>✓</li> <li>✓</li> </ul>	-	4	ł	4	24
1	-	4	-	-	20
-	4	-	-	4	17
-	-	4	-	4	16
-	4	4	-	-	14
- <i>-</i>	-	-	4	-	13
-	4	4	-	4	11
-	-	4	-	4	10
-	-	4	-	-	8
-	4	-	~	-	8
4	-	4	1	-	8
-	4	4	4	4	7
-	-	-	1	4	5
-	-	4	4	4	3

•Encore and SACT have higher data completeness than other data sources and are the most likely data sources to hold more detailed information on chemotherapy.

•Historical SACT data (2010-2012) coverage is highly incomplete and only reaches similar levels to that in Encore in 2013. However, there are a sizeable proportion of cases that have a record of chemotherapy in only one of these two data sources.


•Encore data are highly incomplete for the chemotherapy drug(s) administered, with more than 2800/3960 chemotherapy records having no information or 'unknown' drug. So for a more detailed, but probably incomplete, analysis of chemotherapy treatment patterns, SACT data for 2013 can be used.

## Integrating data

- We know that patients often need multidisciplinary treatment
- Clear 'gold-standard'
  - 60Gy/ 30# with chemotherapy
  - Common variations
    - 30Gy/6#
    - ~40Gy/ 15#

## Radiotherapy attendances for Glioblastoma diagnosed in 2013 in residents of England

Patients treated with combinations of debulking surgery, radiotherapy and chemotherapy



## Preliminary conclusions

- We can link multi-modality treatment data
  - But it is non-trivial
  - Not automatic
  - Requires some assumptions
- This is where data represents services
  - GBM treatment is a good example of multi-modality care
  - We can (and have) 'done' single treatment studies
  - But complex oncology care is harder

## Way forward

- Complete 2013 & 2014 cohort
- Finalise linkage, and decide on final in/out criteria for treatment
- Provide some preliminary analyses of 'whole pathway' treatments
- Use that data to answer key clinical questions
- Link with other data
  - Imaging DIDs